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Purpose: Umeclidinium/vilanterol (UMEC/VI) is a novel fixed dose combination of a 
long-acting muscarinic receptor antagonist (LAMA) and a long-acting beta 2 receptor antagonist 
(LABA) agent. This analysis evaluated the incremental cost-effectiveness ratio (ICER) of UMEC/VI 
compared with tiotropium (TIO), from the Spanish National Health System (NHS) perspective.
Methods: A previously published linked equations cohort model based on the epidemiological 
longitudinal study ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate 
End-points) was used. Patients included were COPD patients with a post-bronchodilator forced 
expiratory volume in 1 second (FEV
1
) #70% and the presence of respiratory symptoms mea-
sured with the modified Medical Research Council dyspnea scale (modified Medical Research 
Council $2). Treatment effect, expressed as change in FEV
1
 from baseline, was estimated from 
a 24-week head-to-head phase III clinical trial comparing once-daily UMEC/VI with once-daily 
TIO and was assumed to last 52 weeks following treatment initiation (maximum duration of 
UMEC/VI clinical trials). Spanish utility values were derived from a published local observa-
tional study. Unitary health care costs (€2015) were obtained from local sources. A 3-year time 
horizon was selected, and 3% discount was applied to effects and costs. Results were expressed 
as cost/quality-adjusted life years (QALYs). Univariate and probabilistic sensitivity analysis 
(PSA) was performed.
Results: UMEC/VI produced additional 0.03 QALY and €590 vs TIO, leading to an ICER 
of €21,475/QALY. According to PSA, the probability of UMEC/VI being cost-effective was 
80.3% at a willingness-to-pay of €30,000/QALY.
Conclusion: UMEC/VI could be considered as a cost-effective treatment alternative compared 
with TIO in symptomatic COPD patients from the Spanish NHS perspective.
Keywords: COPD, cost-effectiveness analysis, cost-utility analysis, umeclidinium/vilanterol, 
tiotropium
Introduction
COPD is a highly prevalent, chronic, progressive respiratory disease. In Spain, the 
EPISCAN study (the Epidemiologic Study of COPD in Spain) estimated a prevalence 
of 10.2% in people aged between 40 and 80 years.1 It is the fourth leading cause of 
death worldwide and is a major cause of chronic morbidity, above diseases such as 
diabetes or depression.2 Chronic, progressive dyspnea is one of the most prevalent 
symptoms of COPD, and it is estimated that approximately 50% of patients continue 
to have symptoms of dyspnea despite receiving treatment.3 The presence of dyspnea is 
associated with deterioration in the quality of life and increased mortality, regardless 
of exacerbations.4,5
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In addition to the impact on the patient, COPD is also 
associated with a high consumption of health care resources 
and costs. In Spain, it is estimated that the annual mean 
health care cost of a COPD patient varies between €1,388 
and €2,154, with the main components of cost being hospi-
talization (44%) and drug treatment (41%).6
The goal of COPD treatment is to reduce symptoms, 
reduce the frequency and severity of exacerbations, and 
improve the prognosis and quality of life of patients.7,8 Long-
acting bronchodilators, which improve lung function and 
reduce symptoms, are the basis of COPD maintenance drug 
therapy.7 There are two types of bronchodilators, long-acting 
β2 receptor agonists (LABA) and long-acting muscarinic 
receptor antagonists (LAMA), which may be used alone 
or in combination. In patients with higher symptoms or in 
whom symptoms persist despite treatment, administration of 
an LAMA + LABA is recommended.7,8
Recently, the fixed-dose combination of the LAMA ume-
clidinium bromide (UMEC) and the LABA vilanterol (VI) 
(Anoro® Ellipta 55/22 µg, GlaxoSmithKline SA, Brentford, 
United Kingdom) indicated as once-daily maintenance bron-
chodilator treatment to relieve symptoms in adults patients 
with COPD9 has been marketed in Spain, providing a new 
alternative treatment for symptomatic patients.
Due to the humanistic and economic burden associated 
with COPD, treatment decisions should be based on the 
analysis of the expected clinical and economic benefits. 
Health care resources allocation demands a rational principle 
and the consequent priority setting. An economic evaluation 
allows for a comparative analysis of alternative actions in 
terms of costs and health outcomes, being considered as a 
valuable tool for decision-making. Efficiency measured in 
economic evaluations is concerned with the relation between 
resource inputs (costs) and either intermediate outputs or 
final health outcomes.10
The aim of this study was to evaluate the cost-effectiveness 
of once-daily UMEC/VI vs the most-frequently used treat-
ment, the LAMA tiotropium (TIO) (Spiriva® Handihaler 
18 µg, Boehringer Ingelheim SA, Ingelheim am Rhein, 
Germany), in symptomatic COPD patients from the perspec-
tive of the Spanish National Health System (NHS).
Materials and methods
The cost-effectiveness analysis was performed using a 
recently published validated model of COPD disease 
progression that allows comparing the long-term effects 
and costs of different treatment options.11 This model was 
adapted to the Spanish settings according to guidelines for 
health technology assessment in Spain and international 
recommendations.12,13 As no experimental or interventional 
research involving patients was applied, and no patient data 
was used, no ethical approval was required.
Disease progression model description
A qualitative conceptual model (CM) of COPD was devel-
oped to identify and describe qualitative causal relationships 
between disease attributes, progression, and outcomes.11 In 
order to do so, a literature review was performed to iden-
tify any prior published CM or literature reporting on the 
impact and association of COPD disease attributes. After 
critical analysis of the literature, a draft CM was devel-
oped based on the literature and expert opinion, and it was 
validated by a Delphi Panel. Delphi results were reviewed 
by a steering group of health economists, epidemiologists, 
and clinicians to determine the attributes, where sufficient 
evidence exists for use in economic modeling.11
Thus, the disease progression CM describes the associa-
tions between the demographic characteristics of patients, the 
central attributes of COPD representing disease progression 
(lung function, symptoms, exacerbations, and exercise toler-
ance), and their impact on health outcomes (expressed in terms 
of quality-adjusted life years [QALYs]) and costs.
Associations between the attributes and health outcomes 
were quantified by Exuzides et al using non-linear regression 
models of random effects, known as risk equations, which were 
developed from the longitudinal epidemiological ECLIPSE 
(Evaluation of COPD Longitudinally to Identify Predictive 
Surrogate End-points) study.14–16 Risk equations represent 
and quantify associations between the central indicators of 
the disease and their impact on HRQoL and mortality. Risk 
equations were estimated for each of the central attributes 
defined in the CM: exacerbations (moderate and severe), lung 
function (measured by forced expiratory volume in 1 second 
[FEV
1
]), COPD symptoms (dyspnea, cough, and/or sputum), 
and exercise capacity (measured by 6-minute walk test distance 
[6MWD]) (equations available in Exuzides et al16). They were 
estimated to predict the effect of baseline and longitudinal 
covariates on the dependent central attribute, on an annual 
basis. Across the risk equations, the baseline variables used 
were age, CVD comorbidities, “Other” comorbidities, smoking 
status, sex, body mass index, 6MWD, fibrinogen level, modi-
fied Medical Research Council (mMRC) grade, St George’s 
Respiratory Questionnaire (SGRQ) score, and prior exacerba-
tions. The predicted outcomes of the risk equations of central 
attributes were used as inputs into the final outcome equations 
for HRQoL (measured by SGRQ score) and mortality.16
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
0.
24
4.
13
8.
15
5 
on
 1
2-
O
ct
-2
01
6
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD 2016:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
125
Cost-effectiveness of UMeC/VI vs TIO in COPD
These risk equations were brought together to estimate 
the progression of COPD in terms of the central attributes 
of the disease through to final health outcomes of (quality 
adjusted) life expectancy, and health service cost. The model 
was therefore implemented as a linked-equation model. The 
model starts with baseline prognostic factors and moves on 
to predicting the central attributes (lung function, exacerba-
tion rate, symptoms, and exercise capacity). The baseline 
variables and longitudinal central associations are then used 
together, to predict the final health outcomes of HRQoL 
utility and survival.
Internal validation compared 3 years of predicted cohort 
experience with results from ECLIPSE. At 3 years, the model 
predicted a survival rate, an annual exacerbation rate, and 
an annual decline in FEV
1
, which fell within the confidence 
limits of the ECLIPSE data.
For adaptation to Spain, a time horizon of 3 years was 
selected, in line with previously published analyses.17 A dis-
count rate of 3% was applied for future costs and effects occur-
ring after the first year based on local recommendations.12 The 
study was made from the perspective of the Spanish NHS, 
which only takes direct health care costs into account.
The results of the cost-effectiveness analysis were 
expressed using the incremental cost-effectiveness ratio 
(ICER) of UMEC/VI vs TIO, calculated using the formula:
 
ICER
Cost Cost
QALY QALY
UMEC/VI TIO
UMEC/VI TIO
=
−
−
 
Compared options and study population
The LAMA TIO was selected as the reference comparator 
as it is the most-widely used treatment in Spain.18
According to the recommendations on LAMA + LABA 
combination therapy,7,8 COPD patients with moderate or 
severe impairment in lung function (post-bronchodilator 
FEV
1
 #70% of predicted normal values), with the presence 
of dyspnea (mMRC score $2) and a low risk of exacerbations 
were included. The remaining baseline characteristics of the 
patients with an impact on the estimated model results were 
defined using local studies and national statistics in order to 
be more representative of the Spanish population;19–21 in the 
cases where this was not possible, the best available published 
source was used (Table 1).
Clinical entry data
effectiveness
The disease progression model allows estimating differ-
ences between treatments in terms of lung function (FEV
1
). 
Differences between UMEC/VI and TIO were determined 
according to the results of the 24-week phase III clinical trial 
that  compared the efficacy of UMEC/VI and TIO in terms of 
trough FEV
1
.22 This clinical trial was a multicenter, randomized, 
blinded, double-dummy, parallel-group study that randomized 
905 patients aged .40 years with moderate-to-very severe 
COPD and an established clinical history of COPD (defined 
by American Thoracic Society/European Respiratory Society 
guidelines). This study found an increase in trough FEV
1
 of 
112 mL for UMEC/VI 55/22 µg compared with TIO 18 µg 
at 24 weeks of treatment. This difference in efficacy between 
treatments was applied during the first year of the time horizon, 
according to the study by Donohue et al,23 which showed the 
sustained effect of UMEC/VI on lung function at 52 weeks. 
As there is no published data for UMEC/VI beyond 52 weeks, 
a conservative scenario that assumed no difference in efficacy 
between the two treatments beyond that time was used.
Utilities
In the initial disease progression model,11,16 quality of life 
was obtained using an adjusted risk equation constructed 
using the SGRQ scores reported in the ECLIPSE study, and 
Table 1 Baseline characteristics of the population included in 
the analysis
Baseline characteristics Base case Source
sex
Female (%) 17 Casanova et al19
Male (%) 83
Mean age (years) 67 Casanova et al19
Body mass index
Casanova et al19low (%) 4.6
Medium (%) 60.3
high (%) 35.1
$1 cardiovascular comorbidity (%) 29 Maleki-Yazdi 
et al22$1 other comorbidity (%) 86
history of exacerbations, $1 (%) 16.6
mMrC score $2 (%) 100
active smokers (%) 29 Casanova et al19
height (m) (mean) 1.676 spanish national 
health survey21
Fibrinogen (µg/ml) (mean) 458.8 Vestbo et al14
agusti et al15
number of exacerbations in 
previous year (mean)
0.27 Maleki-Yazdi 
et al22
Moderate/severe ratio 80:20 hurst et al44
sgrQ score (mean) 42.7 almagro et al20
Post-bronchodilator baseline FeV1 
(%pred) (mean)
46.4% Maleki-Yazdi 
et al22
six-minute walk test (6MWT) (m) 
(mean)
438 Casanova et al19
Abbreviations: mMRC, modified Medical Research Council; SGRQ, St George’s 
Respiratory Questionnaire; FEV1, forced expiratory volume in 1 second.
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subsequently converted to utilities according to the algorithm 
of Starkie et al.24
In this analysis, for better adaptation to the Spanish 
environment, a new risk equation estimated utility values 
according to specific data on Spanish COPD patients obtained 
from an observational study that estimated utility scores in 
these patients.25,26 In this study, utility values were derived 
from the preference-based generic questionnaire EQ-5D-3L, 
applying weighted Spanish societal preferences, obtained 
from a multicenter, observational, cross-sectional study 
that included patients aged $40 years, with spirometrically 
confirmed COPD. The new risk equation was a saturated 
linear regression model explained by the variables from 
the observational study, which were considered to have an 
impact on both utility and the disease progression model 
(explanatory variables). These variables were sex, age, body 
mass index, comorbidities, smoking status, lung function, 
exacerbation history, symptoms measured by mMRC score, 
and the presence of cough and sputum (Table 2). All these 
variables were obtained directly from the local study except 
cough and sputum, which was assumed to correspond to a 
score of $3 in the first two dimensions of the COPD Assess-
ment Test questionnaire collected in the local study.
economic entry data
Costs were counted according to the number of exacerba-
tions (moderate to severe), the costs of follow-up according 
to the frequency of dyspnea symptoms, and the cost of drug 
treatment. All costs were estimated in euros 2015 and were 
adapted from Spanish sources.
The pharmacologic costs associated with UMEC/VI and 
TIO were expressed in terms of the retail price plus value 
added tax (PTP+VAT)27 and were counted as the cost/day 
during the 3-year time horizon of the analysis.
To calculate the cost of exacerbations, a moderate exac-
erbation was defined as one requiring treatment with oral 
corticosteroids and/or antibiotics and a severe exacerbation as 
one requiring hospitalization. The costs associated with each 
episode were estimated from the resource use specified in the 
studies by Miravitlles et al,28,29 resulting in a cost of €70.86 
for moderate exacerbations (considering drug costs, one visit 
to primary care, and one visit to emergency department for 
4.3% of the patients), and €4,349.61 for severe exacerbations 
(considering one visit to primary care, one visit to emergency 
department, and 8 days of hospitalization).
There are no reported data on the annual cost associ-
ated with patient follow-up according to the frequency of 
dyspnea, although one UK study has estimated the costs of 
follow-up according to the severity of dyspnea measured by 
the mMRC score.30 For this reason, the following assumption 
of equivalence between the frequency of the symptoms of 
dyspnea and their severity was made:
•	 Level 1: No symptoms per week = mMRC 0–1
•	 Level 2: Symptoms several days per week = mMRC 2–3
•	 Level 3: Symptoms almost daily = mMRC 4
Using this assumption, the annual cost for each level was 
calculated based on the annual cost of following a COPD 
patient in Spain,31 the distribution of the severity of dysp-
nea in Spain,19 and the distribution of costs in the study by 
Punekar et al (Table 3).30
Table 2 risk equation to incorporate spanish utilities (linear 
regression model)
Variables Effect
Intercept 0.8345
Female (vs male) -0.0875
low BMI (vs mean) -0.0059
high BMI (vs mean) -0.0136
Cardiovascular comorbidities (vs no) -0.0074
Other comorbidities (vs no) -0.0074
smoker (vs ex-smoker) -0.0244
age 0.0012
number of exacerbations -0.0291
Post-bronchodilator FeV1 (%pred) 0.0006
mMrC 2–3 (vs 0–1) -0.1541
mMrC 4 (vs 0–1) -0.5326
Cough and sputum (vs no)a -0.0672
Note: aDefined as answers $3 in the first two dimensions of the CAT (COPD 
assessment Test) questionnaire.
Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in 1 second; 
pred, predicted; mMRC, modified Medical Research Council.
Table 3 Unitary costs of health care resources included in the 
analysis
Type Cost (€) Source
Drug cost (PTP + VaT)
UMeC/VI – 55/22 umeclidinium/
vilanterol powder for inhalation 30 doses
70.25 national 
Formulary 
listing27TIO – 18 µg tiotropium powder for 
inhalation 30 capsules
49.06
Cost per episode of exacerbation
Moderate exacerbation 70.86 Miravitlles 
et al28,29severe exacerbation 4,349.61
annual cost of management according to symptoms
Dyspnea level 1: no symptoms per 
week = mMrC 0–1
511.18 Punekar 
et al30
almagro 
et al20
sicras  
et al31
Dyspnea stage 2: symptoms several days 
per week = mMrC 2–3
681.72
Dyspnea level 3: symptoms nearly every 
day = mMrC 4
901.7
Abbreviations: PTP + VAT, retail price plus value added tax; UMEC/VI, umeclidinium 
and vilanterol; TIO, tiotropium; mMRC, modified Medical Research Council.
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Uncertainty analysis
Deterministic and probabilistic sensitivity analyses were per-
formed to evaluate the uncertainty of some parameters in the 
model results and to determine the robustness of the results.
In the deterministic sensitivity analyses, the influence of 
various parameters on the results of the model was estimated 
by individual modification. Table 4 shows the modified 
parameters and the new values used. In addition, to evaluate 
the uncertainty associated with the development of the new 
risk equation to obtain utilities, alternative equations were 
adjusted as shown in Tables S1–S3.
In the probabilistic sensitivity analysis (PSA) 10,000 
simulations were performed using Monte Carlo methodology32 
simultaneously modifying the coefficients of all risk equations 
(Cholesky decomposition was considered to maintain 
correlation effects), the baseline characteristics (beta and 
normal distributions) of the patients, and the difference in 
efficacy between treatments (normal distribution).
All model calculations were made using Microsoft Excel 
2010.
Results
Base case
The results of the cost-effectiveness analysis of UMEC/VI 
vs TIO after 3 years of treatment are summarized in Table 5. 
Compared with TIO, the improvement in lung function 
observed with UMEC/VI resulted in an increase of 0.03 
QALY. UMEC/VI treatment resulted in additional costs 
of €590, mainly due to the difference in the cost of drug 
treatment. This resulted in an ICER of €21,475/QALY.
Uncertainty analysis
The tornado diagram (Figure 1) shows the results of the 
deterministic sensitivity analysis described in Table 5. The 
ICER ranges between €20,636 and €47,428. The parameters 
with the greatest impact were the modification of the utility 
values (ICER increases if the initial equation based on the 
ECLIPSE study is used), the difference in efficacy between 
treatments (ICER increases with a decreased difference 
in efficacy based on Decramer et al,33 the duration of the 
effect (ICER decreases with increasing duration), and the 
time horizon considered (ICER decreases with decreasing 
time horizon). The other parameters considered produced no 
changes in the ICER.
Figure 2 shows the cost-effectiveness plane with the 
results of the PSA: 99.9% of the simulations are located 
in the first quadrant, representing a higher cost and greater 
effectiveness of UMEC/VI vs TIO. Figure 3 shows the 
acceptability curve of the probability that UMEC/VI is cost-
effective compared with TIO, the probability increases as 
the willingness to pay per QALY gained rises.
Discussion
In today’s health care environment, decision-making must 
be based not only on criteria of efficacy and safety, but also 
on those of efficiency. Cost-effectiveness analyses provide 
information on the economic value of a health intervention, 
Table 4 Deterministic sensitivity analysis values
Parameter Base case Alternative values
Time horizon 3 years 1 year, 5 years
Baseline characteristics spanish population data, clinical 
development of UMeC/VI and eClIPse
Clinical development UMeC/
VI and eClIPse
Efficacy data UMEC/VI vs TIO 112 mL (81.144; P,0.001)  
(Maleki-Yazdi et al22)
60 mL (10.109; P=0.018)
(Decramer et al33)
Duration of efficacy First year First 6 months
entire time horizon (3 years)
Modeling of quality of life spanish utilities (M1) sgrQ
Discount rate for costs and future events 3% (0%–5%)
exacerbation unitary cost (moderate and severe) estimated from Miravitlles et al28,29 (± 20%)
Follow-up cost according dyspnea levels (three 
levels of frequency)
estimated from sicras et al31
Punekar et al30
almagro et al20
(±20%)
Abbreviations: UMEC/VI, umeclidinium and vilanterol; TIO, tiotropium; SGRQ, St George’s Respiratory Questionnaire; ECLIPSE, Evaluation of COPD Longitudinally to 
Identify Predictive surrogate end-points.
Table 5 results of base case
UMEC/VI TIO
health outcomes (QalY) 2.025 1.998
Costs €6,215 €5,625
ICer (€/QalY) €21,475
Abbreviations: UMEC/VI, umeclidinium and vilanterol; TIO, tiotropium; ICER, 
incremental cost-effectiveness ratio; QALY, quality-adjusted life year.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
0.
24
4.
13
8.
15
5 
on
 1
2-
O
ct
-2
01
6
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD 2016:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
128
Miravitlles et al
generally in comparison with the mostfrequently used 
intervention. Thus, cost-effectiveness analyses are tools that 
may aid health care managers and decision makers make 
informed decisions. This analysis studied the economic value 
to the NHS of a new treatment, the combination of UMEC/VI 
vs TIO, the most widely used treatment for COPD in Spanish 
clinical practice.18
In the base case, the ICER of UMEC/VI is €21,475/
QALY compared with TIO, suggesting that UMEC/VI may 
be considered as a cost-effective option vs TIO, as the ICER 
is below the threshold of €30,000/QALY generally accepted 
in Spain.34,35 In the PSA, UMEC/VI was a cost-effective 
option vs TIO in 80.3% of the simulations using the same 
threshold.
The QALY quantifies changes in utility over the life of 
the patient, and it has two components; quality and quantity 
of life, being the most accepted health-related utility measure. 
In the model developed, QALY difference observed between 
compared treatments was a consequence of different cumula-
tive number of exacerbations over the time horizon analyzed, 
6MWT results, percentage of patients with symptoms (dysp-
nea and cough and sputum), quality of life, and survival.
Various international and Spanish economic evaluations 
of COPD have been made.17,36–39 The efficiency of TIO has 
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Figure 1 results of the sensitivity analysis.
Abbreviations: SGRQ, St George’s Respiratory Questionnaire; UMEC/VI, umeclidinium and vilanterol; TIO, tiotropium; Min, minimum; Max, maximum.
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Figure 2 Probabilistic sensitivity analysis results. Cost-effectiveness plane.
Abbreviations: QALYs, quality-adjusted life years; UMEC/VI, umeclidinium and vilanterol; TIO, tiotropium.
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been evaluated in several studies,36–38 which have found it is 
a cost-effective treatment compared with other bronchodi-
lators, such as ipratropium or salmeterol. When comparing 
the present analysis with those already published, it can be 
concluded that both methods, population, outcomes, and 
costs included are similar with the considered ones in the 
model here explained.17
The present analysis is the first to determine the cost-
effectiveness of the combination of two bronchodilators 
compared with monotherapy in the Spanish setting. The 
same analysis has been carried out in the UK with similar 
results, showing that UMEC/VI has a high probability of 
being cost effective vs TIO at £30,000/QALY.40 Recently, 
a cost-effectiveness analysis of combined treatment with 
indacaterol + glycopyrronium from the perspective of the 
Swedish NHS has been published.41 Although in this study 
the comparators used were a free combination or the com-
bination of an inhaled corticosteroid + LABA, the results 
support the efficient use of LAMA + LABA treatment in 
symptomatic patients.
Model selection is a critical factor in cost-effectiveness 
analyses, since the model must accurately represent the dis-
ease studied. Generally, the models used in COPD are based 
exclusively on pulmonary function as the basis for the transi-
tion between different health states.17 The present analysis 
used a previously published model of disease progression11 
that incorporates exacerbations, symptoms, and exercise 
capacity as measures of the progression of COPD. This 
wider focus on the progression of COPD is in line with the 
latest definitions of the disease based on a multidimensional 
assessment that goes beyond lung function.7,8
The population included in the analysis was symptomatic 
COPD patients with moderate-to-very severe FEV
1
 impair-
ment but with low risk of exacerbations. The use of LAMA + 
LABA combination treatment is recommended in patients 
with higher symptoms or in whom symptoms or obvious limi-
tations in exercise persist despite receiving monotherapy.7,8 
The results obtained here support this recommendation, with 
UMEC/VI being an efficient treatment option compared with 
monotherapy with TIO.
The development of a new risk equation to incorpo-
rate Spanish utilities has various positive points. First, it 
allows better adaptation to the Spanish setting and makes 
the results more robust, being the first published Spanish 
analysis that incorporates utility values of Spanish COPD 
patients. In addition, in the initial disease progression model, 
utility was obtained by mapping of the SGRQ; although 
this technique is useful and commonly used, using utility 
scores obtained directly from generic patient questionnaires 
is recommended whenever possible.25 The study used to 
obtain utilities25,26 did not collect the same variables as those 
included in the initial equation of the disease progression 
model. This might be considered as a limitation, but the 
new risk equation included all available relevant variables, 
and therefore provides the best explanation of the vari-
ance in utility observed in Spanish patients. To evaluate 
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Figure 3 acceptability curve.
Abbreviations: QALY, quality-adjusted life year; UMEC/VIL, umeclidinium/vilanterol.
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the uncertainty of including Spanish utilities, sensitivity 
analysis with alternative equations for obtaining utilities 
was made. The results obtained, shown in Table S3, were 
very similar, except for the M2 equation that did not take 
into account the effect of lung function and therefore could 
not distinguish effects between treatments. With respect to 
the initial risk equation based on the SGRQ, variations in 
FEV
1
 showed less direct impact on utility.
Despite the advantages identified, the analysis had some 
limitations. First, the time horizon used and the limitations 
of long-term extrapolations from studies of limited duration 
should be taken into account, particularly with respect to 
the duration of the effect on the improvement in lung func-
tion observed in clinical trials. Some models with a lifetime 
horizon assume that the benefits in lung function observed 
at the beginning of treatment are maintained over time.17,42 
Although some studies indicate that improvements in lung 
function may last up to 3 years,43 this benefit has not been 
demonstrated in long-term studies. Therefore, most reported 
cost-effectiveness analyses17 use a time horizon between 1 
and 3 years, maintaining the treatment effect during this 
time. In the present analysis, a time horizon of 3 years was 
selected, and a more conservative strategy was adopted in 
which difference in efficacy between treatments was main-
tained for only the first 12 months, which corresponds to the 
maximum duration of studies of UMEC/VI, while the costs 
associated with pharmacological treatment were maintained 
for 3 years.
Another limitation of economic evaluations is related to 
the quality of data. In this case, local Spanish data sources 
were used when available or, in their absence, the best 
available evidence. All assumptions were validated by the 
authors, and a sensitivity analysis was made to evaluate 
uncertainty.
Conclusion
The results of this cost-effectiveness analysis show that 
treatment with UMEC/VI in symptomatic COPD patients is 
a cost-effective option compared with TIO from the perspec-
tive of Spanish NHS, as the ICER was below the threshold 
commonly accepted in Spain to consider interventions as 
efficient.
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Table S1 risk equations developed for utility estimation
Risk equation Scenario Description
M1 Base case saturated linear regression model
M2 sensitivity analysis Reduction in number of variables according to goodness of fit index AIC
M3 sensitivity analysis grouping of frequency and severity of dyspnea: mMrC2 (vs 0–1) and mMrC3–4 (vs 0–1)
M4 sensitivity analysis Variable cough and sputum = score $2 in first two items of CAT
M5 sensitivity analysis Variable cough and sputum = score $4 in first two items of CAT
Abbreviations: AIC, Akaike information criterion; mMRC, modified Medical Research Council; CAT, COPD Assessment Test.
Table S2 Variables considered in each of the risk equations
Base-case sensitivity analysis
Effect
M1 M2 M3 M4 M5
Intercept 0.8345 0.9158 0.8526 0.8345 0.8148
Female (vs male) -0.0875 -0.0902 -0.0819 -0.0875 -0.0749
low BMI (vs mean) -0.0059 – -0.0870 -0.0059 -0.0153
high BMI (vs mean) -0.0136 – -0.0305 -0.0136 -0.0197
Cardiovascular comorbidities (vs no) -0.0074 – -0.0407 -0.0074 -0.0023
Other comorbidities (vs no) -0.0074 – -0.0169 -0.0074 -0.0091
smoker (vs ex-smoker) -0.0244 – -0.0488 -0.0244 -0.0338
age 0.0012 – 0.0012 0.0012 0.0010
number of exacerbations -0.0291 -0.0298 -0.0338 -0.0291 -0.0316
FeV1 (%) post-bronchodilator 0.0006 – 0.0004 0.0006 0.0008
mMrC 2–3 (vs 0–1)a -0.1541 -0.1606 -0.1089 -0.1541 -0.1573
mMrC 4 (vs 0–1)a -0.5326 -0.5390 -0.3041 -0.5326 -0.5275
Cough and sputum (vs no)b -0.0672 -0.0581 -0.0600 -0.0672 -0.0776
Notes: aIn M3, grouping is mMrC 2 (vs 0–1) and mMrC 3–4 (vs 0–1). bIn M4 and M5, cough and sputum are considered as equivalent to the score in the first two items of 
CaT $2 and $4, respectively.
Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in 1 second; mMRC, modified Medical Research Council; –, variable not considered in the model.
Table S3 results obtained considering risk equations developed for utility estimation
UMEC/VI TIO UMEC/VI vs TIO
QALY Cost (€) QALY Cost (€) ∆QALY ∆Cost (€) ICER (€/QALY)
Base case
M1 2.025 6,215 1.998 5,625 +0.0275 +590.1 21,475
M2 2.043 6,215 2.039 5,625 +0.0048 +590.1 123,425
M3 2.021 6,215 1.994 5,625 +0.0271 +590.1 21,794
M4 2.028 6,215 1.999 5,625 +0.0288 +590.1 20,456
M5 2.024 6,215 1.997 5,625 +0.0271 +590.1 21,759
Abbreviations: UMEC/VI, umeclidinium and vilanterol; TIO, tiotropium; QALY, quality-adjusted life years; ICER, incremental cost-effectiveness ratio.
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